Your Mammogram Letter Says 'Dense.' Here's Where the Experts Split
The summary that arrives after a routine mammogram reads like a form, and for most of its length it is one, right up to the line that says "Your breast tissue is dense." Since September 10, 2024, the FDA has required every U.S. mammography facility to send each patient one of two standardized paragraphs, either "Your breast tissue is not dense" or "Your breast tissue is dense," and the dense version adds that "in some people with dense tissue, other imaging tests in addition to a mammogram may help find cancers." It does not say which tests, whether you should have one, or who pays for it. Nor does it mention that the experts you might ask gave opposite answers this spring, when the American College of Physicians and the American College of Radiology went public with a disagreement that is still unresolved in October, Breast Cancer Awareness Month.
What "Dense" Means, and What It Doesn't
Dense is a description of how your breast tissue looks on an image, not a diagnosis.
Breasts are built from fatty tissue plus glandular and fibrous tissue, and radiologists grade the mix on a four-step scale called BI-RADS. According to the National Cancer Institute, about 10% of women have breasts that are almost entirely fatty (category A), about 40% have scattered areas of dense tissue (B), about 40% have heterogeneously dense breasts (C), and about 10% have extremely dense breasts (D). The "dense" in your letter means C or D, which is why nearly half of the women 40 and older who get mammograms receive it. You cannot feel density during a self-exam, and neither can a clinician; only a radiologist reading the image can see it. Density tends to run in families, rises with menopausal hormone therapy and a lower body mass index, and drifts down with age and after having children, so the letter you get at 42 may not be the one you get at 58.
Two separate problems come with it. Dense tissue and tumors both show up white on a mammogram, so a small cancer can hide against a white background, and the test is less sensitive as a result. Dense tissue is also a risk factor in its own right: women with dense breasts have a higher chance of developing breast cancer than women with fatty ones. The reassuring detail, per the NCI, is that once other health and tumor factors are accounted for, women diagnosed with breast cancer who have dense breasts are no more likely to die of it than women with fatty breasts.
The 2024 Baseline, and the Evidence Gap Inside It
The U.S. Preventive Services Task Force's April 2024 recommendation, which remains its current statement on breast cancer screening, calls for a mammogram every other year for all women from 40 through 74, a B grade. On dense breasts it stopped short. The Task Force concluded there was not enough evidence to recommend for or against adding ultrasound or MRI, labeled it an "I statement," and said that women with dense breasts should still start screening at 40 and talk with their clinicians about follow-up testing.
"Insufficient evidence" is easy to misread. It does not mean the extra tests fail; it means the studies that would show whether they save lives have not been done. The strongest data so far come from the DENSE trial in the Netherlands, which enrolled women aged 50 to 75 with extremely dense breasts and a normal mammogram. Women invited to an MRI on top of the mammogram had 2.2 invasive interval cancers per 1,000, meaning cancers that surfaced between scheduled screens, compared with 4.7 per 1,000 in the mammogram-only group. The cost was a false-positive rate of roughly 80 per 1,000 women screened, each one a callback and sometimes a biopsy, and the ACP's 2026 review found no supplemental test with supporting evidence that it lowers breast cancer deaths.
April's Split Between Physicians and Radiologists
On April 17, 2026, the American College of Physicians published updated guidance in the Annals of Internal Medicine for average-risk women, defined as those without a personal history of breast cancer, a known gene variant such as BRCA1 or BRCA2, a strong familial risk syndrome, or high-dose chest radiation at a young age. It calls for biennial mammography from 50 to 74, a shared decision rather than a default for women in their 40s, and a conversation about stopping at 75. For women with category C or D breasts, it says clinicians should consider supplemental 3D tomosynthesis and should not use supplemental MRI or ultrasound, citing low-certainty evidence and the burden of false positives.
The American College of Radiology and the Society of Breast Imaging answered the same day with a statement titled "New ACP Breast Cancer Screening Guidelines May Cost Lives." They urge annual screening from age 40 and a risk assessment by 25, warned that later and less frequent screening could contribute to thousands of additional breast cancer deaths each year, and called stopping at tomosynthesis for dense breasts out of step with current research. The ACR's 2023 recommendations go the other way on extra imaging: women with dense breasts who want supplemental screening should have breast MRI. The American Cancer Society sits between the camps on age, offering annual mammograms from 45 to 54 with the option to start at 40.
| Group | Position for average-risk women with dense breasts |
|---|---|
| USPSTF (2024) | Mammogram every two years from 40 to 74; evidence insufficient for or against supplemental ultrasound or MRI |
| ACP (April 2026) | Biennial mammography from 50, shared decision in the 40s; consider supplemental 3D tomosynthesis; do not use supplemental MRI or ultrasound |
| ACR and SBI | Annual screening from 40; MRI for women with dense breasts who want supplemental screening |
| European Society of Breast Imaging | MRI every two to four years for women 50 to 70 with extremely dense breasts |
The Coverage Rule That Changed on January 1
For many insured women, the biggest practical change of 2026 has little to do with the science. Under the updated Women's Preventive Services Guidelines supported by HRSA, published in the Federal Register on December 30, 2024, non-grandfathered group and individual health plans must now cover, with no copays or deductibles, additional imaging such as MRI, ultrasound or extra mammography views, plus pathology work, when it is indicated to complete breast cancer screening for women at average risk. The guideline text admits that no randomized trials support separate recommendations for dense breasts, then adds that testing to complete screening "may be more common for women with dense breasts."
The fine print matters. Medicare, the Veterans Health Administration, TRICARE and grandfathered plans appear to be exempt, according to the nonprofit DenseBreast-info.org's reading of the rule, and the rule is written for average-risk women. The word "indicated" also does heavy lifting, because your clinician has to order the extra imaging for a documented reason, and the consultancy Mercer noted in 2025 that many employer plans were still treating additional breast imaging as diagnostic care, with deductibles and coinsurance attached. A rule that exists on paper can still arrive as a bill.
Coverage matters because access is thin. A Penn State College of Medicine study in JAMA Network Open, announced on September 10, analyzed 12.6 million insurance records for women aged 40 to 64, drawn from 2008 through 2019, and found that state insurance mandates were associated with about 47 additional breast ultrasounds per 1,000 women screened, against 13 for laws that only required notification. Across the whole sample, just 9% of women had a supplemental ultrasound and 0.6% an MRI within six months of a screening mammogram, even though more than 40% of women 40 and older have dense breasts.
What to Do With the Letter
None of this replaces a conversation with the clinician who knows your history, but a few moves are worth making before that appointment.
- Ask for your category. The letter says only "dense," while the radiologist's report to your doctor names category C or D, and the gap matters because the best trial evidence for MRI sits in category D.
- Check your family history, any known gene variant such as BRCA, and whether you had chest radiation when young.
- Find out whether your scan was 2D or 3D, since tomosynthesis is the ACP's suggested add-on and some centers already use it for the standard exam.
- Before booking any extra test, call the imaging center and your insurer and ask how it will be coded, as screening or as diagnostic, because that one word decides whether a deductible applies.
- Bring questions about your personal risk, the false-alarm rate for the test being offered, and radiation exposure, among others.
Keep the next mammogram on your calendar. The Task Force, the ACP, the ACR and the Cancer Society all keep mammography as the foundation of screening, and none of them treats dense breasts as a reason to skip it.
Outside the United States
The FDA letter is a U.S. rule. England's NHS screening program invites women from age 50 up to their 71st birthday, every three years, and Europe's radiologists have staked out their own position on density, as the table above shows. If you live elsewhere, ask your screening service whether it tells patients their density category at all, because a notification letter like the American one is not a given everywhere.
The last sentence of the FDA's template is the one worth acting on: "Talk to your healthcare provider about breast density, risks for breast cancer, and your individual situation." It reads like boilerplate, but with the guidelines pointing in different directions this fall, that appointment is where your density category, your personal risk and your insurance plan finally meet.